Volume Alert - RCPT 109.86 Receptos Inc $RCPT Hit a high today of 111.70 Closing the day 10:30 at 109.86 +6.88 +6.68% With a day low of 102.70 and a total volume of 1,059,375.
RCPT Recent Posts: http://investorshangout.com/Receptos-Inc-RCPT-87962/
RCPT Receptos Inc Recent Headline News
Money flow positive for Receptos
Seeking Alpha - at Seeking Alpha - 2 hrs 50 mins ago
RCPT: 108.17 (+5.19)
Receptos prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 7:01AM CST
RCPT: 108.17 (+5.19)
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Tue Nov 18, 7:10PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share. The gross proceeds to Receptos from this offering are expected to be $360 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares of common stock to be sold in the offering are being offered by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock. The offering is expected to close on or about November 24, 2014, subject to customary closing conditions.
RCPT: 108.17 (+5.19)
Today In SA PRO: Monday, November 17
SA PRO Top Ideas - Seeking Alpha - Tue Nov 18, 4:00AM CST
Top Idea: Edgewater Technologies by Andreas: Long / Micro-Cap / IT Services / Value / Cyclical Swing / Takeover Target / Outstanding Performance Award Winning Buyside Author / 75% Upside Top Idea: Sungy Mobile by Radiant Research: Short /...
DFS: 64.43 (-0.55), DTSI: 31.90 (-0.79), GOMO: 6.12 (-0.08), GBX: 63.60 (-0.85), EDGW: 8.12 (+0.15), RCPT: 108.17 (+5.19)
Receptos Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire - Mon Nov 17, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
RCPT: 108.17 (+5.19)
Announcing This Week's Outstanding Performance Award Winners - Stephen Simpson And Trading The Spread
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Nov 17, 4:00AM CST
Dear readers, This week's winners of our Outstanding Performance awards share, as per usual, a few key common traits. Both authors are regular and successful authors on Seeking Alpha. Both articles were compelling cases made for undervaluation in...
GBX: 63.60 (-0.85), RCPT: 108.17 (+5.19)
InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST
HAS: 56.24 (+0.12), CJES: 18.27 (+0.29), FB: 73.83 (-0.51), MRC: 21.49 (-0.31), SUMR: 2.82 (-0.01), MYL: 55.73 (-0.51), GOOG: 537.28 (+2.25), GSAT: 2.66 (+0.11), CHRS: 13.20 (+0.04), GGP: 26.44 (+0.53), DVA: 75.18 (-0.05), Q: 57.60 (+0.27), SPW: 92.22 (-0.56), RCPT: 108.17 (+5.19), DATA: 80.14 (-1.96), X: 34.64 (-1.36), PSEC: 9.65 (-0.03), SCHW: 28.53 (-0.23), ERII: 4.86 (-0.04)
Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors
PR Newswire - Fri Nov 14, 7:00AM CST
Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq: RCPT), has been appointed as chairman of the board of directors.
RCPT: 108.17 (+5.19)
Insider Trading Alert - RCPT, EA And FFIV Traded By Insiders
at The Street - Thu Nov 13, 11:30AM CST
Stocks with insider trader activity include RCPT, EA and FFIV
EA: 43.35 (+0.48), FFIV: 126.65 (-1.19), RCPT: 108.17 (+5.19)
Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.17 (+5.19)
Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST
RCPT: 108.17 (+5.19)
Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 108.17 (+5.19)
Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST
RCPT: 108.17 (+5.19)
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 108.17 (+5.19)
Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.17 (+5.19)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.56 (-0.14), WMGI: 28.85 (-0.09), CFN: 57.71 (-0.07), UTHR: 128.68 (+0.47), RCPT: 108.17 (+5.19), WMGIZ: 4.40 (-0.01)
Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 108.17 (+5.19)
Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 46.91 (+0.21), PTLA: 26.73 (-0.56), RCPT: 108.17 (+5.19), IG: 8.98 (-0.29)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.71 (-0.27), ECHO: 26.54 (-0.07), LAYN: 6.93 (-0.17), NVAX: 4.97 (-0.04), SCYX: 9.53 (+0.03), RCPT: 108.17 (+5.19), TRNX: 26.30 (-0.22), IDTI: 17.85 (-0.21), SANM: 24.49 (-0.13)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.92 (-0.15), KSS: 57.40 (+0.27), MU: 32.89 (+0.02), PFE: 30.40 (-0.19), HAL: 48.51 (-0.03), AMGN: 163.10 (+0.86), NQ: 6.99 (-0.01), RGC: 22.53 (-0.28), MS: 35.56 (+0.09), MSG: 72.96 (-0.25), NVAX: 4.97 (-0.04), CQB: 14.46 (-0.01), SRPT: 15.87 (+0.30), RCPT: 108.17 (+5.19), TWTR: 39.69 (-0.92), PTIE: 1.68 (-0.05)
RCPT Recent Posts: http://investorshangout.com/Receptos-Inc-RCPT-87962/
RCPT Receptos Inc Recent Headline News
Money flow positive for Receptos
Seeking Alpha - at Seeking Alpha - 2 hrs 50 mins ago
RCPT: 108.17 (+5.19)
Receptos prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 7:01AM CST
RCPT: 108.17 (+5.19)
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Tue Nov 18, 7:10PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share. The gross proceeds to Receptos from this offering are expected to be $360 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares of common stock to be sold in the offering are being offered by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock. The offering is expected to close on or about November 24, 2014, subject to customary closing conditions.
RCPT: 108.17 (+5.19)
Today In SA PRO: Monday, November 17
SA PRO Top Ideas - Seeking Alpha - Tue Nov 18, 4:00AM CST
Top Idea: Edgewater Technologies by Andreas: Long / Micro-Cap / IT Services / Value / Cyclical Swing / Takeover Target / Outstanding Performance Award Winning Buyside Author / 75% Upside Top Idea: Sungy Mobile by Radiant Research: Short /...
DFS: 64.43 (-0.55), DTSI: 31.90 (-0.79), GOMO: 6.12 (-0.08), GBX: 63.60 (-0.85), EDGW: 8.12 (+0.15), RCPT: 108.17 (+5.19)
Receptos Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire - Mon Nov 17, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
RCPT: 108.17 (+5.19)
Announcing This Week's Outstanding Performance Award Winners - Stephen Simpson And Trading The Spread
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Nov 17, 4:00AM CST
Dear readers, This week's winners of our Outstanding Performance awards share, as per usual, a few key common traits. Both authors are regular and successful authors on Seeking Alpha. Both articles were compelling cases made for undervaluation in...
GBX: 63.60 (-0.85), RCPT: 108.17 (+5.19)
InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST
HAS: 56.24 (+0.12), CJES: 18.27 (+0.29), FB: 73.83 (-0.51), MRC: 21.49 (-0.31), SUMR: 2.82 (-0.01), MYL: 55.73 (-0.51), GOOG: 537.28 (+2.25), GSAT: 2.66 (+0.11), CHRS: 13.20 (+0.04), GGP: 26.44 (+0.53), DVA: 75.18 (-0.05), Q: 57.60 (+0.27), SPW: 92.22 (-0.56), RCPT: 108.17 (+5.19), DATA: 80.14 (-1.96), X: 34.64 (-1.36), PSEC: 9.65 (-0.03), SCHW: 28.53 (-0.23), ERII: 4.86 (-0.04)
Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors
PR Newswire - Fri Nov 14, 7:00AM CST
Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq: RCPT), has been appointed as chairman of the board of directors.
RCPT: 108.17 (+5.19)
Insider Trading Alert - RCPT, EA And FFIV Traded By Insiders
at The Street - Thu Nov 13, 11:30AM CST
Stocks with insider trader activity include RCPT, EA and FFIV
EA: 43.35 (+0.48), FFIV: 126.65 (-1.19), RCPT: 108.17 (+5.19)
Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.17 (+5.19)
Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST
RCPT: 108.17 (+5.19)
Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 108.17 (+5.19)
Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST
RCPT: 108.17 (+5.19)
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 108.17 (+5.19)
Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.17 (+5.19)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.56 (-0.14), WMGI: 28.85 (-0.09), CFN: 57.71 (-0.07), UTHR: 128.68 (+0.47), RCPT: 108.17 (+5.19), WMGIZ: 4.40 (-0.01)
Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 108.17 (+5.19)
Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 46.91 (+0.21), PTLA: 26.73 (-0.56), RCPT: 108.17 (+5.19), IG: 8.98 (-0.29)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.71 (-0.27), ECHO: 26.54 (-0.07), LAYN: 6.93 (-0.17), NVAX: 4.97 (-0.04), SCYX: 9.53 (+0.03), RCPT: 108.17 (+5.19), TRNX: 26.30 (-0.22), IDTI: 17.85 (-0.21), SANM: 24.49 (-0.13)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.92 (-0.15), KSS: 57.40 (+0.27), MU: 32.89 (+0.02), PFE: 30.40 (-0.19), HAL: 48.51 (-0.03), AMGN: 163.10 (+0.86), NQ: 6.99 (-0.01), RGC: 22.53 (-0.28), MS: 35.56 (+0.09), MSG: 72.96 (-0.25), NVAX: 4.97 (-0.04), CQB: 14.46 (-0.01), SRPT: 15.87 (+0.30), RCPT: 108.17 (+5.19), TWTR: 39.69 (-0.92), PTIE: 1.68 (-0.05)
